These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10556200)

  • 1. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients.
    Buzyn A; Petit F; Ostankovitch M; Figueiredo S; Varet B; Guillet JG; Ameisen JC; Estaquier J
    Blood; 1999 Nov; 94(9):3135-40. PubMed ID: 10556200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
    Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
    Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas receptor (CD95)-mediated apoptosis in leukemic cells.
    Komada Y; Sakurai M
    Leuk Lymphoma; 1997 Mar; 25(1-2):9-21. PubMed ID: 9130610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis.
    Lickliter JD; Kratzke RA; Nguyen PL; Niehans GA; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1519-27. PubMed ID: 10517493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
    von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.
    Lewis NR; Pallis M; Russell NH
    Exp Hematol; 2000 May; 28(5):535-42. PubMed ID: 10812243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
    Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
    Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
    Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
    World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Hahne M; Rimoldi D; Schröter M; Romero P; Schreier M; French LE; Schneider P; Bornand T; Fontana A; Lienard D; Cerottini J; Tschopp J
    Science; 1996 Nov; 274(5291):1363-6. PubMed ID: 8910274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
    Xu LN; Zou SQ; Wang JM
    World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas-mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells.
    Rich RF; Green WR
    J Virol; 1999 May; 73(5):3826-34. PubMed ID: 10196277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THP-1 monocytic leukemia cells express Fas ligand constitutively and kill Fas-positive Jurkat cells.
    Bremner TA; Chatterjee D; Han Z; Tsan MF; Wyche JH
    Leuk Res; 1999 Oct; 23(10):865-70. PubMed ID: 10573130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo.
    Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Kim CS; Kim SH; Yoo NJ
    APMIS; 1998 Nov; 106(11):1035-40. PubMed ID: 9890264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.